Chugai Pharmaceutical Co Ltd ADR
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $41.31 billion
- Book Value:
- Revenue TTM:
- $1,259.95 billion
- Operating Margin TTM:
- Gross Profit TTM:
- $783.70 billion
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Chugai Pharmaceutical Co Ltd ADR had its IPO on under the ticker symbol CHGCY.
The company operates in the Healthcare sector and Drug Manufacturers-General industry. Chugai Pharmaceutical Co Ltd ADR has a staff strength of 0 employees.
Shares of Chugai Pharmaceutical Co Ltd ADR opened at $12.76 at the start of the last trading session i.e. 2023-03-20.
The stocks traded within a range of $12.46 - $12.76, and closed at $12.6.
This is a 0% increase from the previous day's closing price.
A total volume of 93,425 shares were traded at the close of the day’s session.
In the last one week, shares of Chugai Pharmaceutical Co Ltd ADR have increased by +2.69%.
Chugai Pharmaceutical Co Ltd ADR's Key Ratios
Chugai Pharmaceutical Co Ltd ADR has a market cap of $41.31 billion, indicating a price to book ratio of 4.6168 and a price to sales ratio of 0.0369.
In the last 12-months Chugai Pharmaceutical Co Ltd ADR’s revenue was $1,259.95 billion with a gross profit of $783.70 billion and an EBITDA of $560.03 billion. The EBITDA ratio measures Chugai Pharmaceutical Co Ltd ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Chugai Pharmaceutical Co Ltd ADR’s operating margin was 42.33% while its return on assets stood at 19.56% with a return of equity of 28.67%.
In Q3, Chugai Pharmaceutical Co Ltd ADR’s quarterly earnings growth was a positive 3.6% while revenue growth was a positive 36.1%.
Chugai Pharmaceutical Co Ltd ADR’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $0.85 per share while it has a forward price to earnings multiple of 18.0505 and a PEG multiple of 17.3444. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Chugai Pharmaceutical Co Ltd ADR’s profitability.
Chugai Pharmaceutical Co Ltd ADR stock is trading at a EV to sales ratio of 0.0347 and a EV to EBITDA ratio of 0.0762. Its price to sales ratio in the trailing 12-months stood at 0.0369.
Chugai Pharmaceutical Co Ltd ADR stock pays annual dividends of $78 per share, indicating a yield of 2.58% and a payout ratio of 35.87%.
Balance sheet and cash flow metrics
- Total Assets
- $1,700.82 billion
- Total Liabilities
- $368.97 billion
- Operating Cash Flow
- Capital Expenditure
- $8.92 billion
- Dividend Payout Ratio
Chugai Pharmaceutical Co Ltd ADR ended 2023 with $1,700.82 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1,700.82 billion while shareholder equity stood at $1,308.63 billion.
Chugai Pharmaceutical Co Ltd ADR ended 2023 with $0 in deferred long-term liabilities, $368.97 billion in other current liabilities, 73202000000.00 in common stock, $1,187.85 billion in retained earnings and $0 in goodwill. Its cash balance stood at $274.04 billion and cash and short-term investments were $545.30 billion. The company’s total short-term debt was $0 while long-term debt stood at $0.
Chugai Pharmaceutical Co Ltd ADR’s total current assets stands at $1,184.57 billion while long-term investments were $0 and short-term investments were $271.25 billion. Its net receivables were $275.42 billion compared to accounts payable of $188.22 billion and inventory worth $313.02 billion.
In 2023, Chugai Pharmaceutical Co Ltd ADR's operating cash flow was $-47452000000.00 while its capital expenditure stood at $8.92 billion.
Comparatively, Chugai Pharmaceutical Co Ltd ADR paid $0.36 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Chugai Pharmaceutical Co Ltd ADR stock is currently trading at $12.6 per share. It touched a 52-week high of $17.49 and a 52-week low of $17.49. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $12.8 and 200-day moving average was $12.85 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 1.6% are held by institutions.
Frequently Asked Questions About Chugai Pharmaceutical Co Ltd ADR
Similar Industry Stocks (Drug Manufacturers-General)
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company’s products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.